ULTRAVIST 300 Drug Patent Profile
✉ Email this page to a colleague
When do Ultravist 300 patents expire, and what generic alternatives are available?
Ultravist 300 is a drug marketed by Bayer Hlthcare and is included in one NDA.
The generic ingredient in ULTRAVIST 300 is iopromide. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the iopromide profile page.
Summary for ULTRAVIST 300
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 86 |
Clinical Trials: | 11 |
Patent Applications: | 2,426 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ULTRAVIST 300 at DailyMed |
Recent Clinical Trials for ULTRAVIST 300
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Duke Clinical Research Institute | Phase 4 |
GE Healthcare | Phase 4 |
Bayer | Phase 4 |
Pharmacology for ULTRAVIST 300
Drug Class | Radiographic Contrast Agent |
Mechanism of Action | X-Ray Contrast Activity |
Anatomical Therapeutic Chemical (ATC) Classes for ULTRAVIST 300
US Patents and Regulatory Information for ULTRAVIST 300
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Hlthcare | ULTRAVIST 300 | iopromide | INJECTABLE;INJECTION | 020220-002 | May 10, 1995 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bayer Hlthcare | ULTRAVIST 300 IN PLASTIC CONTAINER | iopromide | INJECTABLE;INJECTION | 020220-005 | Nov 18, 2008 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ULTRAVIST 300
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bayer Hlthcare | ULTRAVIST 300 | iopromide | INJECTABLE;INJECTION | 020220-002 | May 10, 1995 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ULTRAVIST 300
See the table below for patents covering ULTRAVIST 300 around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Egypt | 14530 | NON-IONIC X-RAY CONTRAST AGENTS | ⤷ Try a Trial |
Ireland | 800467 | ⤷ Try a Trial | |
Norway | 800657 | ⤷ Try a Trial | |
Ireland | 49647 | NON-IONIC X-RAY CONTRAST AGENTS | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |